StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)

Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –

Vertex Pharmaceuticals R&D Focus — Operating expenses dedicated to R&D by Year

R&D Focus — Operating expenses dedicated to R&D (%) (%)

Vertex Pharmaceuticals R&D Focus — Operating expenses dedicated to R&D: 70.0% in FY2025, down 15.0 pts from a year earlier.

Latest, FY2025
70.0%
Period ended Dec 31, 2025
Change on a year earlier
-15.0 pts
85.0% in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below

Where the FY2025 figure comes from

“R&D Investment as a Percentage of Business Operating Expenses (GAAP) 70% 85% 77%”

Source: Vertex Corporate Responsibility / ESG Report (2025-Vertex-Data-Summary.pdf) ↗

Reported in Vertex Corporate Responsibility & Data Summary Reports.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Vertex Pharmaceuticals R&D Focus — Operating expenses dedicated to R&D (%), annual FY2019–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/esg-rd-pct-opex

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?